Oramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
Oramed Pharmaceuticals (NASDAQ:ORMP) Full Year 2023 Results
Key Financial Results
Net income: US$5.53m (up from US$36.6m loss in FY 2022).
EPS: US$0.14 (up from US$0.94 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Oramed Pharmaceuticals Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) also surpassed analyst estimates.
The company's shares are down 13% from a week ago.
Risk Analysis
Be aware that Oramed Pharmaceuticals is showing 3 warning signs in our investment analysis that you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
